<DOC>
	<DOCNO>NCT02583451</DOCNO>
	<brief_summary>This randomize , double-blind , placebo- active-controlled , 4-period crossover study lemborexant healthy adult elderly subject evaluate drive performance</brief_summary>
	<brief_title>Study Evaluate Effect Lemborexant Versus Placebo Driving Performance Healthy Adult Elderly Subjects</brief_title>
	<detailed_description>The study 2 phase , Prerandomization Randomization . The Prerandomization Phase consist 2 period last maximum 21 day : Screening Baseline . The Randomization Phase comprise four , 9-day treatment period ( Treatment Period 1 - Treatment Period 4 ) minimum 14-day washout treatment period , follow-up interval least 14 day Treatment Period 4 end-of-study ( EOS ) visit . Participants randomize 1 12 sequence incomplete block design .</detailed_description>
	<mesh_term>Zopiclone</mesh_term>
	<criteria>1 . Healthy , male female , age 21 year old Screening 2 . Regular time spend bed 7.0 8.5 hour per night 3 . Regular bedtime , define time participant attempt fall asleep , 22:00 hour 01:00 hour , regular waketime , define time participant get bed day , 05:00 hour 09:00 hour 4 . Body mass index ( BMI ) ≥18 &lt; 31 kg/m2 Screening 5 . Subjective sleep onset latency ( sSOL ) &lt; 30 minute subjective wake sleep onset ( sWASO ) &lt; 60 minute Sleep Diary 6 . At least 3 year experience drive least 3000 km per year 7 . Holds valid license drive vehicle European Union ( EU ) confirm Screening visit 8 . Has drive ability practice drive test judge adequate driving instructor 9 . Able communicate adequately ( write verbal ) either Dutch English determine investigator 1 . A current complaint diagnosis insomnia disorder ( per either The Diagnostic Statistical Manual Mental Disorders Version IV [ DSMIV ] Version 5 [ DSM5 ] criterion ) , sleeprelated breathe disorder , periodic limb movement disorder , restless leg narcolepsy , exclusionary score subscale SLEEP50 2 . Habitually nap 3 time per week 3 . Females breastfeed pregnant Screening Baseline ( document positive betahuman chorionic gonadotropin [ BhCG ] test minimum sensitivity 25 IU/L equivalent unit BhCG ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 4 . Females childbearing potential : Had unprotected sexual intercourse within 30 day study entry agree use highly effective method contraception ( eg , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive , vasectomized partner confirm azoospermia ) throughout entire study period 28 day study drug discontinuation . Are currently abstinent , agree use doublebarrier method ( describe ) refrain sexually active study period 28 day study drug discontinuation . Are use hormonal contraceptive stable dose hormonal contraceptive product least 4 week dose agree use contraceptive study 28 day study drug discontinuation . ( NOTE : All female consider childbearing potential unless postmenopausal [ amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ] sterilize surgically [ ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ] ) . 5 . Males successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( ie , childbearing potential practicing highly effective contraception throughout study period 28 day study drug discontinuation ) . No sperm donation allow study period 28 day study drug discontinuation . 6 . Clinically significant illness require medical treatment Screening Baseline 7 . Any clinically abnormal symptom organ impairment find medical history Screening Baseline physical examination , vital sign , ECG finding , laboratory test result require medical treatment 8 . Has QT interval correct use Fridericia 's formula interval ( QTcF interval ) &gt; 450 m demonstrate repeat ECGs ( repeat initial ECG show correct QT interval ( QTc ) &gt; 450 m ) Screening Baseline 9 . Has history family history congenital QT prolongation history risk factor torsade de pointes ( eg , heart failure , hypokalemia , family history long QT syndrome ) , use concomitant medication prolong QT/QT interval correct heart rate ( QTc interval ) 10 . Has systolic blood pressure ( BP ) &gt; 140 mmHg ( age 2159 ) &gt; 150 mmHg ( age ≥60 ) diastolic BP &gt; 90 mmHg ( age ) Screening Baseline 11 . Has rest heart rate &lt; 50 ≥100 beats/min Screening Baseline 12 . Has history drug alcohol dependency abuse ( define DSM5 criterion ) within approximately 2 year Screening 13 . Any suicidal ideation intent without plan within 6 month Screening Period ( ie , answer `` Yes '' question 4 5 Suicidal Ideation section CSSRS ) 14 . Habitually consume 14 drink per week ( female ) 21 drink per week ( male ) 15 . Has positive alcohol breathalyzer test Screening Baseline checkin 16 . Smokes 6 cigarette per day habitually unwilling abstain smoking cigarette even spend clinic discharge drive test 17 . Habitually consume 3 cup caffeinated beverage per day 18 . Used prohibited prescription overthecounter ( OTC ) concomitant medication within 1 week prior start Sleep Diary Screening Period 19 . Transmeridian travel across 3 time zone 2 week Screening , Screening Baseline plan transmeridian travel across 3 time zone study 20 . A positive urine drug test Screening unwilling refrain use illegal recreational drug marijuana study 21 . Hypersensitivity study drug excipients zopiclone 22 . Participated ( receive investigational product ) another clinical trial le 1 month ( 5 elimination halflives investigational product ) dose currently enrol another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>